On Tuesday, regulators updated the public on their almost three-year-old inquiry into PBMs’ anticompetitive business practices. The report is not positive for the drug middlemen, which immediately criticized it as one-sided.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More